AbbVie is acquiring two local biotechs — but won’t detail its plans for them


AbbVie Inc. isn't saying much about its plans for Cerevel Therapeutics Inc. after announcing it would acquire the neuroscience firm for nearly $9 billion.

Previous Cathy Jacobson, Froedtert Health — Executive of the Year | Honorable Mention
Next Nashville behavioral, mental health companies merge to create Peregrine Health